| abstract |
The present invention is a selective 5-HT2C receptor agonist for the treatment of 5-HT2C related disorders, including obesity, obsessive compulsive disorder, depression and anxiety, and the 6-substituted 2,3,4,5-tetrahydro- 1H-benzo [d] azepine is provided.n n n <Formula I>n n n n n n n n Wherein R 6 is —C≡CR 10 , —OR 12 , —SR 14 or —NR 24 R 25 , other substituents are as defined in the specification.n n n Selective 5-HT2C receptor agonist, 6-substituted 2,3,4,5-tetrahydro-1H-benzo [d] azepine, obesity, obsessive compulsive disorder |